Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

Valneva SE (NASDAQ:VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.Lyme disease is a bacterial infection transmitted to humans by infected ticks, often presenting with an early “bull’s-eye” rash and flu-like symptoms such as fever, headache, and fatigue.The results showed a strong anamnestic immune response and a favorable safety profile six months after a third booster dose (month 48) in all age groups, confirmin ...